v3.26.1
Segment Reporting and Disaggregation of Relevant Expense Captions (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting
The following table presents information about reported segment revenues, segment profit, and significant segment expenses.
Three Months Ended
June 30,		Six Months Ended
June 30,
(in millions)2026202520262025
Revenues:
INGREZZA net product sales$716.5 $624.4 $1,373.3 $1,169.6 
CRENESSITY net product sales183.5 53.2 336.8 67.7 
VYKAT XR net product sales54.3 — 54.3 — 
Other revenues (1)
4.7 9.9 9.1 22.8 
Total revenues959.0 687.5 1,773.5 1,260.1 
Less:
Cost of revenues, excluding amortization of acquired intangible assets23.2 10.3 36.9 18.5 
Research and development:
External research and development 168.5 120.6 316.5 228.5 
Payroll and benefits115.4 72.2 199.9 147.2 
Milestones0.3 15.1 22.9 60.5 
Other research and development (2)
42.5 36.4 83.6 71.3 
Total research and development326.7 244.3 622.9 507.5 
Acquired in-process research and development1.5 — 22.7 0.1 
Selling, general, and administrative439.7 286.3 758.2 562.8 
Amortization of acquired intangible assets16.4 1.0 16.5 2.0 
Gain on sale of business, net of transaction costs— — (28.6)— 
Interest expense2.9 — 2.9 — 
Unrealized (gain) loss on equity investments
(1.2)6.7 (26.5)37.3 
Investment income and other, net
(12.4)(20.6)(40.5)(42.3)
Provision for income taxes
17.8 52.0 66.7 58.8 
Net income
$144.4 $107.5 $342.3 $115.4 
_________________________
(1) Other revenues primarily consist of royalties earned on AbbVie Inc. net sales of elagolix and Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation) net sales of valbenazine.
(2) Other research and development consists of indirect costs incurred for the benefit of multiple research and development programs, including facility-based expenses (such as rent expense) and other overhead allocations.